Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...
MarketWatch26d
Sanofi Teams Up With RadioMedix, Orano in $352 Mln Deal for Cancer Therapy -- Update
With the deal, Sanofi enters the race to develop a type of cancer medicine that has drawn attention from big pharma companies. It follows Bristol-Myers Squibb's $4.1 billion acquisition of ...
FiercePharma4d
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
BioPharma Dive4d
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
FiercePharma26d
Sanofi completes build out of $554M pandemic-ready modular plant for vaccines, biologics
In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.
MedCity News4d
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Sanofi’s Enjaymo, the only approved drug ... company’s rare disease portfolio is comprised of assets from its 2022 acquisition of EUSA Pharma, a developer of drugs for rare cancers.
Benzinga.com4d
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...
Business Times14d
Lenders line up more than 10 billion euros for Sanofi health unit buyout
BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout of Sanofi’s consumer health division ... billion euros of senior debt to back bids for the ...
STAT27d
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...
MedCity News9d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
Benzinga.com15d
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval (UPDATED)
Also Read: Sanofi’s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows. Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd ...
Reuters11d
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...